Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause, Including COVID-19 TORONTO, Ontario -…
Vasomune Therapeutics Announces Clinical and Scientific Advisory Board Esteemed Leaders in Translation, Therapeutic Development and Critical Care Medicine TORONTO, Ontario – (Business Wire) – May 11, 2020 – Vasomune Therapeutics,…
Vasomune Therapeutics Appoints Meenu Chhabra to its Board of Directors Industry Leader Joins Vasomune’s Board of Directors as the Company Transitions to Clinical Development of AV-001 for the treatment of COVID-19/Pathogen-induced…
An article in USA Today describes certain risks associated with contraction of the COVID-19 coronavirus, specifically the major cause of lethality being Acute Respiratory Distress Syndrome (ARDS). The article can…
Coronavirus (COVID-19) kills by inducing Acute Respiratory Distress Syndrome (ARDS). According to a recent article in The Lancet, 12 out of 41 (29%) COVID-19 patients from Wuhan, China developed ARDS…
Vasomune Therapeutics is currently attending the 38TH ANNUAL JPM HEALTHCARE CONFERENCE, San Francisco, California
Vasomune Therapeutics is a private biotechnology company developing the next generation of medications to harness the body’s ability to defend against illness by modifying the host vascular endothelial response.